Latest Conference Articles

February 9th 2018, 11:59pm

SGO Winter Meeting

Adjuvant therapy, regardless of the treatment modality, did not improve overall survival compared with observation for women with early stage, uterine-confined leiomyosarcoma.

February 9th 2018, 11:52pm

SGO Winter Meeting

The administration of stereotactic body radiation therapy through the use of CyberKnife therapy appears to be a safe and effective salvage treatment for women with previously irradiated, locally recurrent gynecologic cancer.

February 9th 2018, 10:51pm

SGO Winter Meeting

Kathleen Moore, MD, discusses combination strategies with immunotherapy for patients with ovarian cancer.

February 9th 2018, 10:39pm

Genitourinary Cancers Symposium (ASCO GU)

Data from the first 13 evaluable patients enrolled in a phase II study of SM-88 showed a reduction in circulating tumor cells, a slowing of prostate-specific antigen increase, and delayed radiographic progression of disease in nonmetastatic prostate cancer.

February 9th 2018, 9:57pm

SGO Winter Meeting

An analysis of black women of Caribbean descent with type I or type II endometrial cancer showed that this population expressed significant differences in genetic variations compared with a nationwide population of patients with endometrial cancer.

February 9th 2018, 5:16pm

Genitourinary Cancers Symposium (ASCO GU)

The PARP inhibitor olaparib appeared to complement the antitumor activity of the PD-L1 inhibitor durvalumab in unselected men with metastatic castrate-resistant prostate cancer, according to findings from a phase II study presented at the 2018 Genitourinary Cancers Symposium.

February 9th 2018, 9:05am

Genitourinary Cancers Symposium (ASCO GU)

Elizabeth Plimack, MD, director of Genitourinary Clinical Research at Fox Chase Cancer Center, discusses 2 studies reported at the 2018 Genitourinary Cancers Symposium in patients with nonmetastatic M0 castration-resistant prostate cancer (CRPC).

February 9th 2018, 4:32am

SGO Winter Meeting

Ahmed N. Al-Niaimi, MD, assistant professor of obstetrics and gynecology, University of Wisconsin School of Medicine and Public Health, discusses the future role for cytoreductive surgery for the treatment of patients with ovarian cancer.

February 9th 2018, 4:26am

SGO Winter Meeting

Erin K. Crane, MD, MPH, gynecologic oncologist, Levine Cancer Institute, Carolinas HealthCare System, discusses the impact of PARP inhibitors for patients with ovarian cancer.

February 9th 2018, 3:40am

Genitourinary Cancers Symposium (ASCO GU)

Monika Joshi, MD, assistant professor, Penn State Hershey Medical Center, discusses a phase Ib study of durvalumab (Imfinzi) and radiation therapy (DUART) followed by adjuvant durvalumab in patients with urothelial carcinoma.

February 6th 2018, 3:00am

Genitourinary Cancers Symposium (ASCO GU)

A new model based on 6 clinical factors may be able to predict overall survival for patients with advanced urothelial cancers being treated with the PD-L1 inhibitor atezolizumab.

February 6th 2018, 3:00am

Genitourinary Cancers Symposium (ASCO GU)

The addition of docetaxel (Taxotere) to frontline long-term hormone therapy for advanced prostate cancer improved quality of life and reduced the need for subsequent therapy, contributing to lower overall costs in the nonmetastatic setting.

February 6th 2018, 3:00am

Genitourinary Cancers Symposium (ASCO GU)

Apalutamide (ARN-509) reduced the risk of metastasis or death by 72% in patients with nonmetastatic castration-resistant prostate cancer, according to findings from the phase III SPARTAN trial.

February 6th 2018, 3:00am

Genitourinary Cancers Symposium (ASCO GU)

The combination of atezolizumab and bevacizumab reduced the risk of progression or death by 26% compared with sunitinib for patients with untreated PD-L1–positive metastatic renal cell carcinoma.

February 6th 2018, 3:00am

Genitourinary Cancers Symposium (ASCO GU)

Treatment with the combination of enzalutamide and androgen deprivation therapy reduced the risk of metastases or death by 71% compared with ADT alone in patients with nonmetastatic castration-resistant prostate cancer.

January 21st 2018, 3:23am

Gastrointestinal Cancers Symposium (ASCO GI)

Treatment with the PD-1 inhibitor pembrolizumab elicited promising progression-free survival and overall survival results in patients with advanced hepatocellular carcinoma who received previous treatment with sorafenib.

January 21st 2018, 2:20am

Gastrointestinal Cancers Symposium (ASCO GI)

Sequencing regorafenib before cetuximab showed superior overall survival compared with the reverse sequence in patients with metastatic colorectal cancer following failure of standard chemotherapy.

January 21st 2018, 12:28am

Gastrointestinal Cancers Symposium (ASCO GI)

Michael J. Overman, MD, associate professor, department of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center, discusses the updated findings from CheckMate-142 in metastatic colorectal cancer during the 2018 Gastrointestinal Cancers Symposium.

January 21st 2018, 12:26am

Gastrointestinal Cancers Symposium (ASCO GI)

Ghassan K. Abou-Alfa, MD, medical oncologist, Memorial Sloan Kettering Cancer Center, discusses the results of the CELESTIAL trial in advanced hepatocellular carcinoma during the 2018 Gastrointestinal Cancers Symposium.

January 20th 2018, 10:30pm

Gastrointestinal Cancers Symposium (ASCO GI)

Induction treatment with nab-paclitaxel plus gemcitabine demonstrated a time to treatment failure of 8.8 months for patients with newly diagnosed locally advanced pancreatic cancer.